Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.
The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.
"I am thrilled to announce the enrollment of the first patient in our US-based study," stated Acarix President & CEO Aamir Mahmood. "This study has the potential to transform the rapid assessment of non-obstructive CAD, streamline ER processes, and establish a protocol at UC Davis and emergency departments nationwide for safely discharging low-risk chest pain patients.”
